Form 4: Capricor Therapeutics CFO Acquires Shares and Options

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, acquired shares and stock options on January 2, 2025, according to a recent SEC filing.

Summary

• Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, acquired 3,342 shares of common stock on January 2, 2025, at a price of $0.
• These shares were received as fully vested Restricted Stock Units for services provided to the company.
• Bergmann also acquired two stock option grants on the same date, one for 75,000 shares and another for 6,170 shares, both with an exercise price of $14.96.
• The 75,000 share option vests monthly starting February 1, 2025, while the 6,170 share option is fully vested immediately.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing detailing insider transactions. It is neither particularly positive nor negative, but rather a standard disclosure. The acquisition of shares and options by the CFO could be seen as a slightly positive sign of confidence.

Positives

• The acquisition of shares and options by the CFO could be seen as a positive sign of confidence in the company's future.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions and is common for publicly traded companies. It provides transparency into the compensation and ownership structure of the company's executives.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of compensation for executives in the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of the 75,000 share option, with monthly vesting over four years, is a typical vesting structure for executive stock options.
• The immediate vesting of the 6,170 share option is less common but can be used as a performance incentive or a sign-on bonus.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates the CFO's confidence in the company.

Key Dates

Keywords

Capricor Therapeutics, SEC Form 4, insider trading, stock options, restricted stock units, Anthony Bergmann, CFO, equity compensation